Is NGAL the Troponin of the kidney?

By On 15. January 2012 · 2 Comments · In BioPorto

An article in Clinical Laboratory Online, written by Dr. Marlies Ostermann and Professor David Bennet from Guys&St.Thomas Hospital in London asks that very question.

Besides praising NGAL as the new marker, the article tries to set some claims, which a “kidney troponin” must face.

1: It must be cheap, excact and precise.

2: The test must offer further information besides what is otherwise at disposal.

3: The testresult must affect clinical decisions, and improve the result for the patient.

Only number 3 is still lagging behind, but improvements are being made, new therapies are being pursued.

So could NGAL be the kidney’s equivalent to the heart’s  Troponin?

The article states that it ALMOST certainly is, but there is still a bit to go before reaching the finishline.

About Karl M. Bidstrup

Tidligere ejer af Medicoinvestor.com Strategien har gennem mange år været at profitere på etablerede aktier, og brænde det hele af på Bioporto... Sad but true. Kontakt mig på medicoinvestor(A)gmail.com hvis du har en million du ikke ved hvor du skal gemme, så skal jeg nok holde den for dig. 🙂

No related posts.

Tagged with: • • • •
 

2 Responses to Is NGAL the Troponin of the kidney?

  1. NGAL A Biomarker of acute kidney injury- where are we now? | MedicoInvestor says:
    4. October 2012 at 08:57

    […] Is NGAL the Troponin of the kidney? […]

    Reply
  2. Stengaard says:
    20. January 2012 at 20:50

    Thank you very much. We intend to keep up the pace 🙂 – If you fel like it – we can link to one another ?

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.